Pharmaceutical

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

ABBV-444is under clinical development by AbbVie and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye).

Jul 1, 2023 - 20:00
ABBV-444is under clinical development by AbbVie and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye).
Read the original article

Tags:

Previous Article

XKDCT-080 by Guangdong Xiankangda Biotechnology for Colorectal Cancer: Likelihoo...

Next Article

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resis...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Banning surprise medical bills is raising costs elsewhere

STAT+: Banning surprise medical bills is raising costs ...

Feb 17, 2024

With Ozempic, Wall Street moves on from a whole other class of medicines

With Ozempic, Wall Street moves on from a whole other c...

Oct 12, 2023

Opinion: Alzheimer’s drug approvals show we need a reevaluation of patient advocacy

Opinion: Alzheimer’s drug approvals show we need a reev...

Dec 19, 2023